Recent attention has focused on the activation of MAP kinase signaling, particularly downstream of the scaffold MEKK3, which is activated in mouse models of CCM, and which binds to CCM2 (Fisher et al., 2015, Uhlik et al., 2003). This evidence concerns the gene MAP3K3 and cerebral cavernous malformation.